PYC Therapeutics
2 clinical trials · 2 recruiting · INDUSTRY
Trials by PYC Therapeutics
RECRUITINGPhase 1NCT06455826
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31...
Sponsor: PYC TherapeuticsEnrolling: 125 locations
Retinitis Pigmentosa 11Retinal DegenerationEye Diseases+2
RECRUITINGPhase 1 / Phase 2NCT06852963
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in...
This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31...
Sponsor: PYC TherapeuticsEnrolling: 166 locations
Retinitis Pigmentosa 11Retinal DegenerationRetinal Disease+2